First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70.
Owonikoko TK, Hussain A, Stadler WM, Smith DC, Kluger H, Molina AM, Gulati P, Shah A, Ahlers CM, Cardarelli PM, Cohen LJ.
Owonikoko TK, et al. Among authors: stadler wm.
Cancer Chemother Pharmacol. 2016 Jan;77(1):155-62. doi: 10.1007/s00280-015-2909-2. Epub 2015 Nov 14.
Cancer Chemother Pharmacol. 2016.
PMID: 26576779
Clinical Trial.